Revision 1

Store at -20C

#14614

HTATIP2/TIP30 Antibody

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W	H	Endogenous	28, 32	Rabbit	#Q9BUP3	10553

Product Usage Information

Application	Dilution
Western Blotting	1:1000

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Specificity/Sensitivity

HTATIP2/TIP30 Antibody recognizes endogenous levels of total HTATIP2 protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding His231 of human HTATIP2 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

The HIV-1 Tat interactive protein 2 (HTATIP2, TIP30, CC3) is an oxidoreductase that was originally identified as a metastatic tumor suppressor and Tat-mediated proapoptotic gene transcription cofactor (1,2). HTATIP2 protein contains a short-chain dehydrogenase (SDR) domain and a NADPH binding motif important for HTATIP2 interaction with importins and inhibition of nucleocytoplasmic transport (3,4). Research studies demonstrate that induced overexpression of HTATIP2 predisposes cells to apoptosis by inhibiting the nuclear transport of important signaling proteins (e.g. p53, activated notch1) and several key targets of the DNA repair process (5-7). HTATIP2 is part of a protein complex, with Rab5a, endophilin B1, and ACSL4, that may regulate EGFR receptor endosomal trafficking, degradation, and cytoplasmic/nuclear signaling (8,9). Silencing of HTATIP2 promotes tumor cell survival under low glucose conditions by inducing increased expression of mitochondrial respiratory proteins and glucose metabolic enzymes (10).

Background References

1. Shtivelman, E. (1997) *Oncogene* 14, 2167-73.
2. Xiao, H. et al. (2000) *EMBO J* 19, 956-63.
3. El Omari, K. et al. (2005) *J Biol Chem* 280, 18229-36.
4. King, F.W. and Shtivelman, E. (2004) *Mol Cell Biol* 24, 7091-101.
5. Zhao, J. et al. (2008) *Cancer Res* 68, 4133-41.
6. Nakahara, J. et al. (2009) *J Clin Invest* 119, 169-81.
7. Fong, S. et al. (2010) *BMC Cell Biol* 11, 23.
8. Zhang, C. et al. (2011) *J Biol Chem* 286, 9373-81.
9. Li, A. et al. (2013) *Oncogene* 32, 2273-81, 2281e.1-12.
10. Chen, V. and Shtivelman, E. (2010) *Cell Cycle* 9, 4941-53.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting

Cross-Reactivity Key

H: Human

Trademarks and Patents

Limited Uses

separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.